Xaaladda kansarka naasaha
Qiyaastii 10-12% kasta ee bukaannada kansarka naasaha ee adduunka waxay ku sugan yihiin Hindiya, iyo ku dhawaad saddex-meelood laba meelood bukaannada waxaa laga helay kansar heersare ah waqtiga cudurka. Khubaradu waxay falanqeeyeen in ay jiraan 50,000 ilaa 60,000 HER2 bukaan oo qaba kansarka naasaha ee Hindiya, iyo in ka yar 20% bukaannada la xaqiijiyay waxay heleen daawaynta ka hortagga HER2. "Tani waxay la macno tahay in in ka badan 80% bukaanada aysan helin daawayn la beegsanayo, fursadaha daawaynta ugu fiicanna ay lumaan."
According to the data, when receiving targeted therapy based on chemotherapy, the risk of recurrence of HER2-positive kansarka naasaha patients was reduced by about 40%, the risk of death was reduced by nearly 30%, and the ten-year survival rate was increased by more than 8%. At present, the treatment of breast cancer has entered the era of individualized and precise treatment. However, due to different detection levels and analysis levels, different testing institutions in China will give different test results, which will greatly affect the treatment results of patients.
Daraasada kansarka naasaha
Marka loo eego natiijooyinka Jaamacadda Washington ee "JAMA Oncology", khubarada Maraykanku waxay aaminsan yihiin: "Natiijooyinkayagu waxay soo jeedinayaan in natiijooyinka baaritaanka hidda-socodka ay si weyn u kala duwanaan karaan, iyadoo ku xiran hadba baaritaanka bukaanku codsanayo." Khubarada Shabakadda Oncologist Global waxay aaminsan yihiin in bukaannada Hay'adda baaritaanka hidda-socodka ee la xushay ay hubin karto saxnaanta natiijooyinka baaritaanka inta ugu badan ee suurtogalka ah, saxnaanta falanqaynta daawada bukaan-socodka, kana fogaato kala duwanaanshaha natiijooyinka daaweynta.
In 2007, ka Bulshada Maraykanka ee Caafimaadka Bukaanka (ASCO) ayaa ku dhawaaqay in kansarka naasaha 21 ee baaritaanka hidda-socodka waa in loo tixgeliyo bukaanada qaba kansarka naasaha hore kuwaas oo u fiican kuwa qaata estrogen oo aan faafin qanjidhada qanjidhada inta lagu jiro horumarinta qorshaha daaweynta kansarka naasaha. Nidaamka Xarunta Qaranka ee Kansarka (NCCN) ayaa ku talisay isticmaalka kansarka naasaha 21 ee baaritaanka hidda-wadaha ee 2008 tilmaamaha daaweynta kansarka naasaha.
Breast cancer 21 gene test refers to the detection of the expression levels of 21 different genes in breast cancer buro tissues, including 16 breast cancer-related genes and 5 reference genes. This test can provide individualized prediction of treatment effects and 10-year risk of recurrence. prediction. By detecting 21 genes and observing their interactions to determine tumor characteristics, the breast cancer recurrence index and the benefit ratio of chemotherapy can be predicted.
Breast cancer 21 gene test is mainly applicable to newly diagnosed breast cancer patients who are in stage I or II, positive for estrogen receptor, negative for lymph node metastasis, and will be treated with tamoxifen. After menopause, patients with aggressive qanjiro who are positive for lymph nodes and estrogen receptors can also use the 21 gene test to determine the benefit of chemotherapy.
Daaweynta saxda ah ee kansarka naasaha
Kansarka naasuhu maaha hal cudur. Guud ahaan, kansarka naasaha waxaa loo qaybin karaa afar nooc: LuminalA, LuminalB, HER2 positive, iyo triple negative marka loo eego tilmaamayaasha kala duwan sida ER, PR, HER2, iyo Ki67. Luminal A iyo Luminal B waa noocyada ugu badan ee unugyada unugyada kansarka naasaha, oo ka dhigan in ka badan 60% dhammaan kansarka naasaha, waxayna leeyihiin saadaal wanaagsan. Saadaasha HER2 togan iyo saddex laab taban waa mid liidata. Waxaa ka mid ah, kansarka naasaha ee HER2-positive waa nooc-hoosaad halis ah oo kansarka naasaha ah, iyo qiyaastii 20% -30% bukaannada kansarka naasuhu waa HER2-positive. Marka loo eego genotyping-ka kansarka naasaha, hel daaweyn u dhigma iyo dawooyin la beegsaday.
Daawooyinka loogu talagalay kansarka naasaha
Trastuzumab (Herceptin) ayaa la bilaabay 1998 waxayna saameyn wanaagsan ku leedahay bukaanno badan oo HER2-positive kansarka naasaha. Natiijooyinka tijaabooyinka bukaan-socodka waxay soo jeedinayaan in daaweynta trastuzumab adjuvant therapy ay si wax ku ool ah oo wax ku ool ah u yareeyn karto halista soo noqoshada, taasoo ka dhigaysa bukaanno badan oo HER2 ah oo qaba kansarka naasaha hore faa'iido u leh in ka badan 10 sano. Lapatinib (Tykerb) Lapatinib waa afka, dib-u-noqoshada tyrosine kinase inhibitor kaas oo joojiya labadaba unugyada unugyada unugyada unugyada unugyada unugyada unugyada (EGFR, HER1) iyo HER2 tyrosine phosphate Effect ayaa si aad ah uga fiican daawooyinka kaliya ee xannibaya mid ka mid ah bartilmaameedyada. Daawadani waa daawadii labaad ee la beegsaday molecularly ee loo oggolaaday suuqgeynta kansarka naasaha ka dib trastuzumab, badiyaa daawaynta kansarka naasaha ee horumarsan. Bevacizumab (magaca ganacsiga Avastin) Dib-u-soo-celinta bini-aadmiga monoclonal antibody kaas oo xannibaya dhaqdhaqaaqa noolaha ee dhexdhexaadinta VEGF iyadoo si tartan ah loogu xirayo soo-dhoweeyayaasha VEGF oo leh factor koritaanka endothelial vascular (VEGF) . Waa daawadii ugu horreysay ee la oggolaaday si loo joojiyo angiogenesis-ka buro. Lenatinib (Neratinib / Noratinib) waa af, aan laga noqon karin HER1,2 iyo 4 inhibitor. Afatinib Afatinib waa daawo molecule yar oo afka laga qaato oo leh saameyn aan la bedeli karin oo ka hortag ah HER1,2 iyo 4.
